• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Scholar Rock Holding (SRRK) Stock Dropped, So What Is Behind The Latest Attention?

    Simply Wall St·08/31/2026 07:17:35
    Listen to the news

    Why this regulatory shift matters for Scholar Rock Holding stock

    Scholar Rock Holding (SRRK) is in focus after regulatory updates on its lead SMA therapy apitegromab. The company removed Catalent Indiana from key filings, advanced an alternate facility, and secured a more streamlined path in Japan.

    Scholar Rock Holding's share price has been strong over 2026, with a 30 day share price return of 22.21% and a year to date share price return of 35.05%. The 1 year total shareholder return of 77.03% points to momentum that has been building over time rather than fading. Recent regulatory headlines around apitegromab, set against a very large 3 year total shareholder return of more than 8x, suggest investors are reacting to changes in perceived approval and launch risk, even though the stock pulled back 2.46% on the day to close at US$57.80.

    Scan other rare disease and biotech stocks showing similar regulatory momentum and product catalysts through the curated 19 high quality undiscovered gems that investors are watching alongside Scholar Rock Holding today.

    After a 3 year total shareholder return of more than 8x and a sharp recent run, Scholar Rock Holding now offers a very different entry point. Does the current valuation still compensate you for the regulatory and execution risks ahead?

    Most Popular Narrative: 2.6% Undervalued

    Scholar Rock Holding's most followed narrative points to a fair value slightly above the last close of $57.80, which puts the recent regulatory moves into sharper context.

    Regulatory progress around apitegromab, including preparation for BLA resubmission in the U.S. and an ongoing MAA review in Europe, could support a transition from a development stage profile to a revenue generating commercial business, with direct implications for future revenue and earnings.

    Read the complete narrative.

    The fair value story for Scholar Rock Holding leans heavily on a steep revenue ramp, improving margins and a future earnings multiple that sits well above sector norms. It may be useful to understand which assumptions play the largest role in that calculation.

    Result: Fair Value of $59.31 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, Scholar Rock Holding still faces key swing factors, including potential setbacks in apitegromab regulatory reviews and the risk that launch spending may outpace early product uptake.

    Find out about the key risks to this Scholar Rock Holding narrative.

    Next Steps

    The sentiment around Scholar Rock Holding is clearly mixed, with both meaningful risks and real potential rewards in play. If you want to move quickly and shape your own view based on the underlying data, take a closer look at the 2 key rewards and 3 important warning signs.

    Looking for more Scholar Rock Holding style investment ideas?

    If you want to keep your edge and not miss what other investors are already screening, use the tools below to uncover fresh opportunities beyond Scholar Rock Holding.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.